ALXO

1.0502.94%
SG

Scott Garland

Independent Director

Mr. Scott Garland, MBA, is Independent Director of Hexagon Bio, Inc. from 2026 and serves as Independent Chairman from July 2026. Mr. Garland is Director of Enliven Therapeutics, Inc. from January 7, 2026. He serves as Independent Chairman of Board of LB Pharmaceuticals Inc since February 2024. He has been Independent Director of ALX Oncology Holdings Inc. since November 29, 2022 and serves as its Chairman since June 30, 2026. He serves as Director of Olema Oncology, Inc. (formerly known as Olema Pharmaceuticals, Inc.) since October 2023. He also served as Venture Partner at Vida Ventures Advisors, LLC since November 2023 until 2024. He served as an Independent Director at Day One Biopharmaceuticals, Inc. since August 2021 until April 23, 2026. Mr. Garland served as the Chief Executive Officer at PACT Pharma, Inc. from March 5, 2021 to February 2023. He had been a Director of Calithera Biosciences, Inc. since July 2020 until 2023. Prior to PACT, Mr. Garland served as the President, Chief Executive Officer and Director of Portola Pharmaceuticals Inc. (which was acquired by Alexion in 2020) from October 08, 2018 to July 2020. Prior to Portola, Mr. Garland served as Chief Commercial Officer and Senior Vice President at Relypsa, Inc. from October 2014 to March 31, 2017 and served as its President from March 31, 2017 to October 1, 2018. Mr. Garland served as an Executive Vice President and Chief Commercial Officer at Exelixis, Inc. from October 25, 2011 to October 2014. Prior to joining Exelixis, from April 2002 to October 2011, Mr. Garland held positions at Genentech, Inc. Mr. Garland is a seasoned biotechnology and pharmaceutical industry veteran with sales, marketing and commercialization experience in the pharmaceutical and biopharmaceutical industry as well as his extensive management experience at publicly-traded companies biopharmaceutical companies. Since 2009, Mr. Garland served as Vice President of Genentech's Avastin franchise, the largest product at Genentech and one of the top five oncology products in the world, where he led the U.S. sales and marketing efforts for the drug. At Genentech, he served as Vice President of hematology marketing and sales, overseeing the Rituxan franchise and as a Marketing Director on the Tarceva franchise. Before Genentech, he held several positions in sales and marketing at Amgen from July 1997 to April 2002. He spent at Merck & Co., Inc., including as professional sales representative from July 1991 to July 1995. He served as an Independent Director of Karyopharm Therapeutics Inc. from November 03, 2014 to May 21, 2020. Mr. Garland received B.S. in Biological Sciences from California Polytechnic State University, San Luis Obispo. He holds an MBA from Duke University’s Fuqua School of Business.

Positions